Elan Bio-Ethicals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-07-2024
- Paid Up Capital ₹ 0.12 M
as on 09-07-2024
- Company Age 35 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.95 M
as on 09-07-2024
- Revenue -10.92%
(FY 2022)
- Profit 1.80%
(FY 2022)
- Ebitda 28.44%
(FY 2022)
- Net Worth -2.87%
(FY 2022)
- Total Assets 10.89%
(FY 2022)
About Elan Bio-Ethicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.12 M.
The company currently has active open charges totaling ₹1.95 M.
Vidyadhar Sawant and Dandu Raju serve as directors at the Company.
- CIN/LLPIN
U24239MH1989PTC050605
- Company No.
050605
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Feb 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Elan Bio-Ethicals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vidyadhar Sawant  | Director | 06-Sep-2013 | Current |
| Dandu Raju | Director | 07-Feb-1989 | Current |
Financial Performance of Elan Bio-Ethicals.
Elan Bio-Ethicals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 10.92% decrease. The company also saw a slight improvement in profitability, with a 1.8% increase in profit. The company's net worth dipped by a decrease of 2.87%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Elan Bio-Ethicals?
In 2020, Elan Bio-Ethicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Elan Pharma (India) Private LimitedActive 27 years 6 monthsVidyadhar Sawant and Dandu Raju are mutual person
Elan Techno Services Private LimitedActive 24 years 5 monthsVidyadhar Sawant and Dandu Raju are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 09 Dec 1999 | ₹1.00 M | Open |
Canara Bank Creation Date: 13 Aug 1998 | ₹0.32 M | Open |
Canara Bank Creation Date: 05 May 1995 | ₹0.30 M | Open |
How Many Employees Work at Elan Bio-Ethicals?
Unlock and access historical data on people associated with Elan Bio-Ethicals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Elan Bio-Ethicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Elan Bio-Ethicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
